Introduction to Cognitive Recovery in Cirrhosis

Covert hepatic encephalopathy (CHE) presents a significant clinical challenge in hepatology, as it often remains undiagnosed despite its profound impact on a patient’s quality of life. Recently, a multicentre randomized controlled trial published in Aliment Pharmacol Ther has provided robust evidence that Rifaximin for Covert HE effectively improves cognitive performance. This finding is particularly relevant for clinicians managing cirrhosis-related complications, as early intervention can potentially prevent the progression to overt hepatic encephalopathy.

Trial Design and Cognitive Improvement

The study utilized an open-label randomized design involving 50 patients with cirrhosis and associated CHE. Researchers randomized participants to receive either rifaximin or no treatment for a period of 12 weeks. Consequently, the primary endpoint focused on changes in Stroop test performance, a validated measure of psychomotor speed and executive function. Notably, the rifaximin group demonstrated a significant improvement in Stroop test scores compared to the control group. Furthermore, patients who were not taking synthetic disaccharides at the start of the study experienced even more pronounced cognitive gains with rifaximin therapy.

Impact of Rifaximin for Covert HE on Clinical Outcomes

Beyond cognitive scores, the trial investigated several secondary clinical parameters. Rifaximin treatment led to a significant reduction in cirrhosis-related adverse events. While serum ammonia levels and overall gut microbial diversity did not show drastic changes between the groups, rifaximin specifically altered certain bacterial taxa. Specifically, there was a notable loss of the [Eubacterium] brachy group in patients receiving the drug. These selective changes in the gut environment may explain the systemic improvements observed without requiring a complete overhaul of the microbiome.

The Role of the Stroop Test in Monitoring Response

This study highlights the Stroop test as a highly sensitive tool for evaluating treatment response in patients with CHE. In contrast to other psychometric tests that might not capture subtle improvements, the Stroop test successfully identified the cognitive benefits of Rifaximin for Covert HE. Therefore, clinicians should consider integrating digital or smartphone-based versions of the Stroop test into routine practice to identify and monitor patients who may benefit from rifaximin before they experience a major decompensation event.

Frequently Asked Questions

What is the primary benefit of using Rifaximin for Covert HE?

The primary benefit is the significant improvement in cognitive performance, specifically in psychomotor speed and executive function as measured by the Stroop test. Additionally, it helps reduce the frequency of cirrhosis-related adverse events.

Does rifaximin significantly change serum ammonia levels in CHE patients?

In this specific randomized trial, no significant changes were observed in serum ammonia levels or NCT-B scores, suggesting that the clinical benefits may be mediated through other pathways such as gut microbiome modulation rather than just ammonia reduction.

Can rifaximin be used as monotherapy for patients not on lactulose?

Yes, the study found that patients not receiving synthetic disaccharides (like lactulose) at baseline showed a significantly greater improvement in Stroop test performance when treated with rifaximin.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Inada H et al. Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial. Aliment Pharmacol Ther. 2026 May 06. doi: 10.1111/apt.70712. PMID: 42092293.

Bajaj JS et al. Rifaximin monotherapy is more effective than lactulose for reducing risk of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality: an analysis of two randomized trials. ACG Annual Meeting. 2024.

Jiang et al. Smartphone-based Stroop Test, EncephalApp: What is the optimal cutoff for diagnosing minimal hepatic encephalopathy? World J Hepatol. 2023;15(11):1234-1245.